Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Point-of-Care Diagnostics & Global Health 2018

Bernhard Weigl's Biography

Bernhard Weigl, Director, Center for In-Vitro Diagnostics, Intellectual Ventures/Global Good-Bill Gates Venture Fund

Dr. Bernhard H Weigl is the Director of the Center for In-Vitro Diagnostics at Intellectual Ventures/Global Good (IV/GG) and an Affiliate Professor at the University of Washington, Department of Bioengineering. The Global Good unit of Intellectual Ventures is directly funded by Bill Gates.

At IV/GG Dr. Weigl leads work to develop the next generation of highly sensitive diagnostic assays for diseases of relevance in developing countries, including TB, cervical cancer, and malaria. His team has recently demonstrated the most sensitive rapid assay for malaria to date. Previously he led the PATH Diagnostics Group where he oversaw global health diagnostics programs funded by a variety of sources such as NIAID and NIBIB, the Grand Challenges program of the Bill and Melinda Gates Foundation, USAID, and the PATH Health Innovation Portfolio. He also served as Portfolio Leader for Non-Communicable Disease Diagnostics and as Director of the National Institutes of Health-funded Center for Point-of-Care Diagnostics for Global Health. His current work focuses on diagnostic technology R&D with relevance to Global Health applications including ultra-sensitive strip-based immunoassays, molecular assays in cartridge and digital formats, novel assay formats, and other biotechnology research for low resource settings.

Before joining PATH, both at the University of Washington and at Micronics, Inc. (Redmond, Washington, now a wholly owned subsidiary of Sony Corporation of America) where he was a scientific cofounder), Dr. Weigl led teams that developed both instrument-based and stand-alone microfluidic medical diagnostic disposables, including the first FDA-approved instrument-free microfluidic test, the ABORhCard®.
His scientific interests include traditional and paper-based microfluidics as well as any assay platform that allows simplification and integration of previously complex assays. As chronic diseases, and especially diabetes, are emerging as a major health threat in developing countries he is now also focusing on their diagnosis, screening, and treatment. Other areas of interest include diagnostics-related health systems topics such as more rational diagnostic algorithms, and evaluation and selection of the most appropriate diagnostic tool for a particular application using metrics beyond sensitivity and specificity. He has led projects across the diagnostics value chain, from invention and proof of principle though product introduction and support.

He received his M.Sc (Mag. rer. nat.) and Ph.D. (Dr. rer. nat.) from Karl-Franzens-University Graz and has completed post-doctoral studies at the University of Southampton and the University of Washington. He has authored more than 130 scientific publications and is an inventor on over 80 US patents and published patent applications.

Bernhard Weigl Image

Advancing the Performance of Low Cost Diagnostics For Global Health

Monday, 1 October 2018 at 15:00

Add to Calendar ▼2018-10-01 15:00:002018-10-01 16:00:00Europe/LondonAdvancing the Performance of Low Cost Diagnostics For Global HealthPoint-of-Care Diagnostics and Global Health 2018 in Coronado Island, CaliforniaCoronado Island,

We will present lab and field results with recently developed lateral flow and similar assays for global health. Our group’s mission is to develop assays for use in global health applications that are as sensitive as the best conventional diagnostic assays (in some cases even better) while retaining cost, simplicity, and usability advantages. For our lateral flow assay work we have developed a 3D modeling platform for paper-based assays and are using it to determine the theoretical limit of a particular assay variant, as well as a rapid array-based empirical optimization system for lateral flow assays. Together, these approaches allow the development of more sensitive assays with shortened development time. We will describe the assay optimization methods we employ, as well the use of these methods in the development of several assays under development, including ones for malaria, and TB.

Add to Calendar ▼2018-10-01 00:00:002018-10-03 00:00:00Europe/LondonPoint-of-Care Diagnostics and Global Health 2018Point-of-Care Diagnostics and Global Health 2018 in Coronado Island, CaliforniaCoronado Island,